The Kringle V-Protease Domain Is a Fibrinogen Binding Region within Apo(a)

Summary

Lp(a) binds directly to fibrin and competes for the interaction of plasminogen with this substrate. This competition may play a role in the proatherothrombogenic consequences of high Lp(a) levels. Previous studies by us and others showed that apo(a) Kringle IV-10 competes for the interaction of Lp(a) with plasmin-treated fibrinogen. However, kringle IV-10 cannot account for the entire high affinity interaction of Lp(a) with fibrinogen. Therefore, we tested the hypothesis that the apo(a) kringle V protease-like domain (KV-PD) could interact with plasmin-treated fibrinogen. We cloned the apo(a) KV-PD region from a human liver cDNA library. Fusion apo(a) KV-PD was expressed in COS 7 cells and purified from the conditioned media. Western blotting of the apo(a) KV-PD protein revealed two bands migrating with apparent molecular weights of 45K and 48K. When fusion apo(a) KV-PD was treated with O-glycosidase and neuraminidase, the higher molecular weight band disappeared suggesting that the apo(a) KV-PD was O-glycosylated. Apo(a) KV-PD bound to plasmin-treated fibrinogen in a dose-dependent fashion. An EC₅₀ of 3.9 ± 0.2 μM was determined for this interaction. Treatment of the apo(a) KV-PD with O-glycosidase did not significantly affect its ability to bind to plasmin-treated fibrinogen. In addition, apo(a) KV-PD competed for the binding of ¹²⁵I-Lp(a) to plasmin-treated fibrinogen. An IC₅₀ of 7.90 ± 0.95 μM was obtained. Our data suggest that the KV-PD of apo(a) shares binding sites on plasmin-treated fibrinogen with Lp(a) and also may participate in the interaction of the Lp(a) particle with plasmin-treated fibrinogen.

Keywords

Apo(a) - kringle - fibrinogen

^* Dr. Madison’s present address is: Edwin L. Madison, Ph. D., Director, Molecular Biology, Corvas International, Inc., 3030 Science Park Road, San Diego, CA 92121

• References

• 1 Loscalzo J. Lipoprotein(a). A unique risk factor for atherothrombotic disease. Arteriosclerosis 1990; 10 (Suppl. 05) 672-9.
• 2 Nordestgaard BG. The vascular endothelial barrier – selective retention of lipoproteins. Current Opinion In Lipidology 1996; 7 (Suppl. 05) 269-73.
• 3 Simionescu M, Simionescu N. Proatherosclerotic events: pathobiochemical changes occurring in the arterial wall before monocyte migration. Faseb Journal 1993; 7 (Suppl. 14) 1359-66.
• 4 Fless GM, Rolih CA, Scanu AM. Heterogeneity of human plasma lipoprotein (a). Isolation and characterization of the lipoprotein subspecies and their apoproteins. J Biol Chem 1984; 259 (Suppl. 18) 11470-8.
• 5 McLean JW. et al. cDNA sequence of human apolipoprotein(a) is homo-logous to plasminogen. Nature 1987; 330 6144 132-7.
• 6 Eaton DL. et al. Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen. Proceedings of the National Academy of Sciences of the USA 1987; 84 (Suppl. 10) 3224-8.
• 7 Lucas MA, Fretto LJ, McKee PA. The binding of human plasminogen to fibrin and fibrinogen. J Biol Chem 1983; 258 (Suppl. 07) 4249-56.
• 8 Wiman B, Wallen P. The specific interaction between plasminogen and fibrin. A physiological role of the lysine binding site in plasminogen. Thrombosis Research 1977; 10 (Suppl. 02) 213-22.
• 9 Whitaker AN. et al. The binding of glu- and lys-plasminogens to fibrin and their subsequent effects on fibrinolysis. Thrombosis Research 1980; 19 (Suppl. 03) 381-91.
• 10 Fleury V, Anglés-Cano E. Characterization of the Binding of Plasminogen to Fibrin Surfaces: The Role of Carboxy-Terminal Lysines. Biochemistry 1991; 30: 7630-8.
• 11 Loscalzo J. et al. Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis 1990; 10 (Suppl. 02) 240-5.
• 12 Miles L. et al. Interaction of Lipoprotein(a) with the Extracellular Matrix. Fibrinolysis and Proteolysis 1998; 12: 79-83.
• 13 Rouy D. et al. Apolipoprotein(a) and plasminogen interactions with fibrin: a study with recombinant apolipoprotein(a) and isolated plasminogen fragments. Biochemistry 1992; 31 (Suppl. 27) 6333-9.
• 14 Harpel PC, Gordon BR, Parker TS. Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin. Proceedings of the National Academy of Sciences of the USA 1989; 86 (Suppl. 10) 3847-51.
• 15 Xue S. et al. Comparison of the effects of Apo(a) kringle IV-10 and plasminogen kringles on the interactions of lipoprotein(a) with regulatory molecules. Thromb Haemost 1999; 81 (Suppl. 03) 428-35.
• 16 Lou XJ. et al. Fibrinogen deficiency reduces vascular accumulation of apolipoprotein(a) and development of atherosclerosis in apolipoprotein(a) transgenic mice. Proc Natl Acad Sci USA 1998; 95 (Suppl. 21) 12591-5.
• 17 Lawn RM. et al. Atherogenesis in transgenic mice expressing human apolipoprotein(a). Nature 1992; 360 6405 670-2.
• 18 Palabrica TM. et al. Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nature Medicine 1995; 1 (Suppl. 03) 256-9.
• 19 Huby T. et al. Characterization of the N-terminal and C-terminal domains of human apolipoprotein(a): relevance to fibrin binding. Biochemistry 1995; 34 (Suppl. 22) 7385-93.
• 20 LoGrasso PV, Cornell KS, Boettcher BR. Cloning, expression, and characterization of human apolipoprotein(a) kringle IV37. J Biol Chem 1994; 269 (Suppl. 34) 21820-7.
• 21 Klezovitch O, Scanu AM. Lys and fibrinogen binding of wild-type (Trp72) and mutant (Arg72) human apo(a) kringle IV-10 expressed in E coli and CHO cells. Arterioscler Thromb Vasc Biol 1996; 16 (Suppl. 03) 392-8.
• 22 Scanu AM. et al. Rhesus monkey lipoprotein(a) binds to lysine Sepharose and U937 monocytoid cells less efficiently than human lipoprotein(a). Evidence for the dominant role of kringle 4 (37). J Clin Invest 1993; 91 (Suppl. 01) 283-91.
• 23 Scanu AM. et al. A single point mutation (Trp72—>Arg) in human apo(a) kringle 4-37 associated with a lysine binding defect in Lp(a). Biochimica et Biophysica Acta 1994; 1227 1-2 41-5.
• 24 Klezovitch O, Edelstein C, Scanu AM. Evidence that the fibrinogen binding domain of Apo(a) is outside the lysine binding site of kringle IV-10: a study involving naturally occurring lysine binding defective lipoprotein(a) phenotypes. J Clin Invest 1996; 98 (Suppl. 01) 185-91.
• 25 Ernst A. et al. Identification of two functionally distinct lysine-binding sites in kringle 37 and in kringles 32-36 of human apolipoprotein(a). J Biol Chem 1995; 270 (Suppl. 11) 6227-34.
• 26 Chenivesse X. et al. Expression of a recombinant kringle V of human apolipoprotein(a): antibody characterization and species specificity. Protein Expression & Purification 1996; 8 (Suppl. 02) 145-50.
• 27 Chang Y. et al. Structure and ligand binding determinants of the recombinant kringle 5 domain of human plasminogen. Biochemistry 1998; 37 (Suppl. 10) 3258-71.
• 28 McCance SG, Menhart N, Castellino FJ. Amino acid residues of the kringle-4 and kringle-5 domains of human plasminogen that stabilize their interactions with omega-amino acid ligands. J Biol Chem 1994; 269 (Suppl. 51) 32405-10.
• 29 Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 1977; 74 (Suppl. 12) 5463-7.
• 30 Zhang X-P, Kamata T, Yokoyama K, Puzon-McLaughlin W, Takada Y. Specific interaction of the recombinant disintegrin-like domain of MDC-15 (Metargidin, ADAM-15) with integrin αvβ3. J Biol Chem 2001; 273 (Suppl. 13) 7345-50.
• 31 Deutsch DG, Mertz ET. Plasminogen: purification from human plasma by affinity chromatography. Science 1970; 170 (Suppl. 962) 1095-6.
• 32 Miles LA, Dahlberg CM, Plow EF. The cell-binding domains of plasminogen and their function in plasma. J Biol Chem 1988; 263 (Suppl. 24) 11928-34.
• 33 Shepherd J, Bedford DK, Morgan HG. Radioiodination of human low density lipoprotein: a comparison of four methods. Clinica Chimica Acta 1976; 66 (Suppl. 01) 97-109.
• 34 Miles LA. et al. Interaction of Lp(a) with plasminogen binding sites on cells. Thromb Haemost 1995; 73 (Suppl. 03) 458-65.
• 35 Fraker PJ, Speck Jr JC. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun 1978; 80 (Suppl. 04) 849-57.
• 36 Scanu AM, Edelstein C. Kringle-dependent structural and functional polymorphism of apolipoprotein (a). Biochimica et Biophysica Acta 1995; 1256 (Suppl. 01) 1-12.
• 37 Bonen DK. et al. Expression of a recombinant apolipoprotein(a) in HepG2 cells. Evidence for intracellular assembly of lipoprotein(a). J Biol Chem 1997; 272 (Suppl. 09) 5659-67.
• 38 Sangrar W, Marcovina SM, Koschinsky ML. Expression and characterization of apolipoprotein(a) kringle IV types 1, 2 and 10 in mammalian cells. Protein Engineering 1994; 7 (Suppl. 05) 723-31.
• 39 Makino K, Furbee JW, Scanu AM, Fless GM. Effect of glycation on the properties of lipoprotein(a). Arterioscler Thromb Vasc Biol 1995; 15 (Suppl. 03) 385-91.
• 40 Hughes SD. et al. Lipoprotein(a) vascular accumulation in mice. In vivo analysis of the role of lysine binding sites using recombinant adenovirus. J Clin Invest 1997; 100 (Suppl. 06) 1493-500.